Graves' ophthalmopathy is probably the most difficult management problem for the thyroidologist. This review aims to highlight recent advances in our knowledge of the condition in the fields of diagnosis, aetiology and treatment, but it will become apparent that much remains to be understood of the aetiology of Graves' ophthalmopathy which consequently impairs optimal management of the condition.
Graves' ophthalmopathy is probably the most difficult management problem for the thyroidologist. This review aims to highlight recent advances in our knowledge of the condition in the fields of diagnosis, aetiology and treatment, but it will become apparent that much remains to be understood of the aetiology of Graves' ophthalmopathy which consequently impairs optimal management of the condition.
Diagnosis
The presence of characteristic eye signs, namely periorbital oedema, chemosis, injection of the sclerae, exophthalmos, lid retraction and ophthalmoplegia in any combination, together with hyperthyroidism, present no difficulty in diagnosis. Problems may arise however if the patient is not and has not been thyrotoxic, in which case the condition is termed ophthalmic Graves' disease (OGD) ; in this subgroup the signs are often unilateral, raising the possibility of a retro-ocular space-occupying lesion in the differential diagnosis.
Biochemical investigations
In OGD thyroid hormone levels (total or free) by definition are not elevated. However, it should be remembered that patients with Hashimoto's thyroiditis may have eye signs which are also covered by the term OGD (Ormston et al. 1973) , so that T3 and T4 may be either normal or low in OGD and occasionally minor elevations of free T3 levels are seen in OGD (Teng & Yeo 1977) . In a sequential study of 27 euthyroid patients with OGD followed for three years, one became hyperthyroid and 7 hypothyroid (Teng & Yeo 1977) and therefore long-term follow up of euthyroid OGD patients is important.
The TSH response to TRH is abnormal in about half of the patients with OGD, being impaired or absent in 40% and exaggerated in 7% (Teng & Yeo 1977) . As expected, a close correlation was also found in this study between T3-induced suppression of thyroidal radioactive iodine uptake and the results of the TRH test, so that the latter alone will suffice as a diagnostic test.
Immunological investigations
Thyroglobulin and microsomal antibodies occur in about 75% of patients with OGD, reflecting in part the presence of Hashimoto's thyroiditis in some of these subjects. Such antibodies are readily measured and are valuable markers for OGD. TSH receptor antibodies, measured by their displacement of radiolabelled TSH from its thyroid receptor in vitro, are positive in 40% of OGD patients ) and thyroid-stimulating antibodies, measured by the thyroid slice-cAMP release assay, were found in all 6 patients tested with OGD and an impaired TSH response to TRH; 4 subjects with OGD and a normal TRH test did not have such antibodies (Zakarija et al. 1980) . The use of such assays adds little to the diagnostic information more easily available from the TRH test and tests for conventional thyroid autoantibodies.
Other investigations
Diagnosis by orbital radiography, ultrasonography or venography has now been supplanted by CT scanning due to the improvements in-spatial resolution of new generation scanners. The hallmarks of Graves' ophthalmopathy have been fully reviewed elsewhere (Trokel & Jakobiec 1981) , the most characteristic change being enlargement of the extraocular muscles with sparing of the tendinous insertion, thus distinguishing the swelling from that due to pseudotumour or inflammatory myositis ( Figure 1 ). Retro-ocular primary and metastatic tumours may be readily visualized and the idiopathic orbital inflammation termed 'pseudotumour' can also be distinguished successfully from Graves' ophthalmopathy, although unilateral cases of pseudotumour may be confused with other mass lesions (Enzmann et al. 1976) . Diagnostic confusion may still result from CT scan appearances, as shown by two recent case reports in which OGD was mistaken for pseudotumour (Feek et al. 1981 ) and lymphoma subsequently found in a patient thought to have OGD (Burrows & Barnett 1981) . This latter case also belies the adage that unilateral protrusion of greater than 8 mm is usually due to tumour and less than 8 mm to other causes.
Ophthalmological assessment
The successful management of Graves' ophthalmopathy demands a joint approach by an ophthalmologist and endocrinologist. Full ophthalmological assessment is mandatory and sequential measurements of visual acuity and fields, Hess charts, colour vision and proptosis provide unequivocal evidence of deterioration or improvement. To this list has recently been added assessment of the intraocular pressure on upward gaze (Gamblin et al. 1983 ). An increase of 3 mmHg or more over the pressure in the primary position is abnormal and is found in about 60% of patients with Graves' disease without exophthalmos. It is likely that an abnormal rise is due to pressure on the globe caused by an enlarged or restricted inferior rectus muscle. This is a readily performed diagnostic test which is useful for detecting patients in whom ophthalmopathy is clinically inapparent, but there are diurnal changes in the values obtained (unpublished observations) and the presence of an abnormal value does not distinguish between ophthalmopathy and other causes of eye muscle restriction including tumour, myositis (pseudotumour) or previous surgery. However, in the differential diagnosis of these conditions, the presence of bilateral changes in intraocular pressure would favour Graves' ophthalmopathy as the cause of what may appear clinically to be unilateral proptosis.
.._._ Figure 1 . Midorbital CT scan of a patient with ophthalmic Graves' disease showing the swollen extraocular muscles, especially the medial recti, and enlargement of the lacrimal glands. Another appearance-which may be found on CT scanning is bowing of bony wall of the ethmoid sinus Aetiology Many of the hypotheses advanced to account for Graves' ophthalmopathy are only of historic interest. However, one such suggestion, namely that excessive thyroid-stimulating hormone (TSH) secretion accounted for both hyperthyroidism and exophthalmos (the latter by a direct action of TSH on the eye; Dobyns 1950) was later extended by Kohn & Winand (1975) . They demonstrated that partial proteolysis of TSH yielded an exophthalmosproducing factor (EPF) as tested in vivo in guinea pigs. Furthermore, the binding of EPF to guinea pig retro-ocular tissue in vitro was enhanced by an IgG found only in Graves' patients with exophthalmos (Winand & Kohn 1972) .
The three major problems with accepting a TSH-derived EPF as pathogenic are: (1) TSH secretion is suppressed in Graves' disease (conversely exophthalmos is rare in autoimmune hypothyroidism in which TSH is elevated); (2) severe exophthalmos has been reported following total hypophysectomy (Furth et al. 1962) ; and (3) it is unlikely that EPF would affect extraocular muscle, which does not have TSH receptors, yet this is probably the site of the primary lesion in Graves' ophthalmopathy (Trokel & Jakobiec 1981) .
Our lack of understanding of the immunological abnormality responsible for Graves' ophthalmopathy reflects our relative ignorance of autoimmune processes in man, particularly in diseases such as this for which no animal model exists. It has been suggested that similar mechanisms account for both Graves' thyroid disease and ophthalmopathy, since several groups have found evidence of ocular involvement in virtually all cases of thyrotoxic Graves' disease using ultrasonography (Werner et al. 1974) or measurements of exophthalmos (Amino et al. 1980) or raised intraocular pressure (Gamblin et al. 1983 ). However, identical ophthalmopathy can occur in patients with Hashimoto's thyroiditis and in subjects with no detectable thyroid abnormality who rarely go on to develop hyperthyroidism (Teng & Yeo 1977) . This multi-faceted association with autoimmune thyroid disease, the benign nature of the condition in the majority of patients contrasting with the dramatic and unpredictable changes of congestive ophthalmopathy in a subset (2-5%) of patients, and the tendency for spontaneous remission to occur, are all clinical features which imply a complex pathogenesis unlike that of the classical organ-specific, autoimmune conditions. Autoimmune mechanisms implicated in the production of Graves' ophthalmopathy can be divided into the following three main groups.
Immune complex-mediated injury Extraocular muscles bind thyroglobulin and also immune complexes of this autoantigen with thyroglobulin antibodies (Konishi et al. 1974) . It was proposed that thyroglobulin and such complexes could be pathogenic and that their fixation in the retro-ocular tissues was the consequence of possible lymphatic drainage from the thyroid to the orbit (Kriss 1970) . Others have confirmed that such localized immune complexes do occur in ophthalmopathy (Mullin et al. 1977) but two questions remain unsettled: are only thyroglobulinantithyroglobulin complexes transported from the thyroid to the orbit and are these pathogenic? No published data indicate that other thyroid or non-thyroid antigens exist in orbital immune complexes, and yet one would expect that complexes containing the microsomal antigen would also be demqnstrable. Indeed, microsomal antibodies are more prevalent in Graves' serum than thyroglobulin antibodies and the latter do not fix complement so that their phlogistic potential is limited. There is some indirect evidence against a role for immune complex-mediated injury: first, the presence of circulating immune complexes, which are complement fixing, does not correlate with eye involvement (Brohee et al. 1979) ; and secondly, membranous glomerulonephritis, which is likely to be the result of immune complex deposition, is a rare occurrence in Graves' disease and is unaccompanied by worsening of the eye signs (Weetman et al. 1981) . Finally, the relevance and even the actual existence of thyroid-orbit lymphatic drainage remains to be settled but would seem dubious for a priori reasons, particularly in view of the frequent occurrence of unilateral eye disease and the gravitational dependence of such drainage.
Humoralfactors
A common aetiological factor in Graves' thyroid disease and ophthalmopathy is clearly an attractive idea. The correlation between ophthalmopathy and TSH-receptor antibodies (measured as long-acting thyroid stimulator), seemed to provide a link but the association is incomplete and the occurrence of ophthalmic Graves' disease in the absence of TSH receptor antibodies also confounds this hypothesis (McKenzie 1968 . It would seem that if autoantibodies are implicated in ophthalmopathy, they are likely to be directed against the retro-ocular tissues, and-there is evidence for local antibody synthesis by plasma cells which infiltrate the extraocular muscles (Trokel & Jakobiec 1981) . Perhaps because of this local synthesis, there was no reactivity of serum from patients with ophthalmopathy when tested against human or animal eye muscle or lacrimal gland by immunofluorescence or using a haemagglutination assay with membrane and soluble extracts of these tissues (Henderson & Wall 1981) . However, an IgG has been detected in the sera of patients with Graves' ophthalmopathy which binds to porcine retro-ocular muscle (and guinea pig Harderian gland) in an enzyme-linked immunosorbent assay (Kendall-Taylor et al. 1984) .-Studies of the frequency of this antibody, its species specificity and complement-fixing ability will clearly be required before conclusions can be made about any pathogenic role; it would also be of interest to compare the results obtained with immunofluorescence methods in view of the apparent discrepancies between this finding and the study of Henderson & Wall (1981) .
A different approach to the question of orbital autoantibodies was recently made by raising monoclonal antibodies from mice immunized with potential orbital antigens (Kodama et al. 1982) . With these monoclonal antibodies, crude orbital homogenates could be fractionated into separate (xeno-) antigens and these purified antigens were then used to screen for serum autoantibodies in patients. Autoantibodies reacting with a soluble extract of human eye muscle were found in the sera of 74% of patients with active ophthalmopathy but surprisingly in none of 16 patients with Graves' disease and no overt eye involvement (in many of whom clinically inapparent ophthalmopathy would be expected). Such autoantibodies are unlikely to be important in the primary aetiology of ophthalmopathy since (1) they are directed against a cytosol component which would normally be inaccessible, and (2) they are only incompletely associated with ophthalmopathy. However, such antibodies could be useful markers of disease activity and could play a role in secondary tissue damage if they have the potential to fix complement or to activate K-cells (antibody-dependent cytotoxicity). A second finding using monoclonal antibodies has been that eye muscle appears antigenically distinct from skeletal muscle; further definition of the location and nature of these unique epitopes is awaited.
Cellular factors
The two standard in vitro tests of T-cell responsiveness to antigen, namely the production of a lymphokine (migration inhibition factor) and the stimulation of cell division (blastogenesis), have been used to study Graves' ophthalmopathy and positive results were obtained using orbital extracts and patient's lymphocytes (Munro et al. 1973 , Mullin et al. 1977 , Wall et al. 1978 . Only limited in vitro experiments have been performed to test the possibility that such sensitized T-cells could be pathogenic. Lymphocytes from patients were shown to lyse radiolabelled lipid vesicles in which thyroglobulin was inserted (Kriss & Mehdi 1979) but, as discussed above, the significance of thyroglobulin in the retro-ocular tissues remains to be established. Destruction of vesicles coated with immune complexes containing thyroglobulin by control lymphocytes (Kriss & Mehdi 1979 ) merely reflects normal K-cell activity. More likely to be of relevance are recent elegant experiments using 111indium-oxine labelled muscle cells in culture as targets for an assay of cytotoxicity. Significant release of isotope was found when lymphocytes from a patient with Graves' ophthalmopathy were cultured with labelled extraocular muscle cells obtained from a normal donor (Blau et al. 1983 ). These lymphocytes had no effect on thigh muscle cells, cytotoxicity was not inhibited by thyroglobulin and normal lymphocytes reacted with neither source of muscle cells. If confirmed in more patients, this is clearly an important observation. However, it is difficult to judge the nature of the cell involved in mediating such cytotoxicity since the K-NK cell lineage does not have the target specificity required to account for these observations and there was no apparent genetic restriction (i.e. identical Class I HLA antigens on target and effector cells) which is necessary for T-cell-mediated cytotoxicity.
A gap in our knowledge which will undoubtedly be filled soon is the surface phenotype of lymphocytes which infiltrate the muscle; such infiltration is likely to be the initiating event in ophthalmopathy (Trokel & Jakobiec 1981) . Demonstration that these are indeed T-cells belonging to the putative 'suppressor/cytotoxic' subset would add impetus to the search for T-cell-mediated cytotoxicity. We have found altered circulating T-cell subsets and an increase in circulating Ia+ T-cells in ophthalmic Graves' disease (Weetman et al. 1983 ) but, as discussed at length elsewhere (Weetman & McGregor 1984) , no conclusions regarding pathogenesis within the target organ can be drawn from such circulatory abnormalities at present. However, reversal of these changes with cyclosporin A (a novel immunosuppressive acting almost exclusively on T-cells) and the rapid resolution of acute early ophthalmopathy produced by this agent provide some indirect evidence to support the involvement of T-cellmediated immune mechanisms in Graves' ophthalmopathy (Weetman et al. 1983 ).
Treatment
As a direct consequence of our ignorance regarding immunomodulation in general and the immunopathogenesis of Graves' disease in particular, treatment for ophthalmopathy is crude. For the majority of patients, nonspecific palliative measures such as diuretics, 5% guanethidine eye drops, artificial tears and elevation of the head of the bed may be useful. Attention to any associated thyroid disease is mandatory, but although there is a belief that the development of hypothyroidism leads to worsening of ophthalmopathy (Thomason & Nusynowitz 1979 ), this was not demonstrable when patients were assessed by exophthalmometry (Gwinup et al. 1982) . In this study, destructive therapy (surgery or radioiodine) for associated hyperthyroidism ameliorated proptosis and propylthiouracil treatment worsened it. Remission of the disease may nonetheless leave the patient with troublesome diplopia; in these 'burnt-out' cases, prisms or surgery to the fibrotic extraocular muscles may be helpful. A natural halt in the progression of ophthalmopathy may also leave patients with the cosmetic problems of proptosis, and surgery to the eyelids (a limited lateral tarsorrhaphy) should be considered for their rehabilitation (de Santo 1980) . The treatment of congestive ophthalmopathy still poses a major management problem. Here one is faced with an acute worsening of pre-existing eye disease which may jeopardize vision because of optic neuropathy or corneal ulceration and which may progress with alarming rapidity. In addition to these patients whose vision is threatened, it is also worth considering those with ophthalmopathy of recent onset in whom diplopia, proptosis or congestive changes are troublesome. In all of these patients, the extraocular muscles are actively inflamed and the varying degrees of oedema contribute to these different manifestations (Trokel & Jakobiec 1981) . Ideal treatment for such patients would suppress the extraocular myositis before secondary changes such as fibroblast activation and subsequent scarring could begin. Such ideal therapy does not currently exist, and there are major problems associated with assessing any novel treatment for severe ophthalmopathy because it is difficult to perform adequately controlled trials and because the established treatments with high-dose steroids or decompression, although not ideal, are known to prevent visual loss.
Orbital decompression A variety of surgical approaches have been advocated but each is associated with complications. Transantral decompression appears to be as effective as the transfrontal procedure in restoring vision and saves the patient a craniotomy (Gorman et al. 1974) . Visual improvement is impressive and occurs in over 90% of patients, but diplopia usually persists or may even appear after decompression (de Santo 1980) . In this series almost 70% of patients required extraocular muscle surgery following decompression. Recently a transorbital approach to medial orbital wall and floor decompression has been suggested to provide good access to the orbital apex with minimal morbidity, but diplopia resulted in 3 of 9 patients (Linberg & Anderson 1981) . Thus decompression by whatever route (1) probably does not alter the natural history of the diseaserepeated decompression may be required (Linberg & Anderson 1981) ; (2) rapidly and effectively restores visual acuity due to optic neuropathy; and (3) does not reliably improve extraocular muscle function and may even worsen it.
Steroids
High-dose steroids are an established first-line treatment for congestive Graves' ophthalmopathy, but there are occasional cases which do not respond. For instance, 77 out of 200 patients in whom transantral decompression was performed (for a variety of indications) were judged not to have been improved by preceding steroid therapy; unfortunately the number who did improve could not be estimated (de Santo 1980) . Failure to respond may well be due to inadequate therapy since there appears to be a variable and high threshold dosage below which steroids are ineffective (Werner 1966) . It is our policy to use dexamethasone 20 mg daily in divided doses as emergency treatment for congestive ophthalmopathy, with rapid reduction of the dose over the succeeding weeks. The majority of patients improve rapidly on this regimen and thereafter they are maintained on a reducing dosage of prednisone. However the morbidity is high and two patients have died, one of gastrointestinal haemorrhage and one of septicaemia. Long-term steroids do not appear worthwhile; using 60 mg prednisone daily to treat diplopia, it was found that any improvement occurred within a month and there was no further change thereafter (Apers et al. 1976 ).
Orbital irradiation
This has been reported to improve optic neuropathy (Covington et al. 1977 ) but there was no major benefit when irradiation was used to treat longstanding ophthalmopathy (Teng et al. 1980) . This inverse relationship between chronicity and response has been confirmed in a study which compared the response to combined irradiation (2000 rad) and steroids with steroids alone (Bartalena et al. 1983) . Only 2 patients with optic neuropathy were treated, both of whom responded, but improvement was also seen in soft-tissue swelling and ophthalmoplegia of recent onset. Combined therapy appeared superior to steroids alone. The authors are aware of several cases of proliferative retinopathy resulting from orbital irradiation, which gives cause for concern.
Immunosuppression Azathioprine was found to be ineffective in 5 patients with chronic ophthalmopathy, but none had optic neuropathy and in 4 the changes were longstanding (Burrow et al. 1970 ). Cyclophosphamide has proved beneficial in patients with optic neuropathy, diplopia and chemosis (Bigos et al. 1979 , Wall et al. 1979 , and this agent would seem worthy of further investigation. Plasma exchange was recently evaluated in 18 patients and found to be of no benefit (Kelly et al. 1983) . This is an important finding in terms of the aetiology, since it provides indirect evidence that serum autoantibodies are unlikely to be involved in the production of the eye disease.
We have begun a trial of cyclosporin A in ophthalmopathy of acute onset and a striking improvement occurred in the first 2 patients treated, one with diplopia and the other with optic neuropathy (Weetman et al. 1983 ). In a further 2 patients, diplopia has also responded well and rapid amelioration was produced in a further patient with optic neuropathy. A single patient, previously on long-term, high-dose steroids, suffered worsening of ophthalmopathy when cyclosporin A was substituted for steroids. Cyclosporin A seems to reduce the size of the extraocular muscles, thus acting at the presumed primary site of the ophthalmopathy. The immunopathological considerations previously discussed predict that cyclosporin A would be of no benefit in longstanding disease and this is indeed the case (Brabant et al. 1984) ; chronicity and recent steroid therapy probably contributed to the single failure we have had with the drug. We have encountered reversible nephrotoxicity and hepatotoxicity in the patients we have treated, but cyclosporin A nonetheless represents an advance over steroids in terms of side effects. It is likely that if these initial observations are confirmed, the drug could be used to treat ophthalmopathy of early onset in the hope of preventing cosmetic problems or chronic disability due to diplopia.
